Peptide-nucleic Acid Solutions
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
40
NCT05212532
A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 9, 2021
Completion: Mar 30, 2022
Loading map...